HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis.

AbstractBACKGROUND:
It is still controversial in the current literature whether omalizumab is beneficial for children with asthma. Given that there is no high-quality meta-analysis to incorporate existing evidence, the purpose of this protocol is to design a systematic review and meta-analysis of the level I evidence to ascertain whether omalizumab is beneficial and safe for children with asthma.
METHODS:
The systematic literature review is structured to adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The following search terms will be used in PUBMED, Scopus, EMBASE, and Cochrane Library databases on June, 2021, as the search algorithm: (omalizumab) AND (asthma) AND (children). The primary outcome is the long-term safety and tolerability of omalizumab. The other outcomes include asthma control, quality of life, use of asthma controller medications, and spirometry measurements and emergency room visits due to asthma, and serum trough concentrations of omalizumab, free and total immunoglobulin E measured. Review Manager software (v 5.3; Cochrane Collaboration) will be used for the meta-analysis.
RESULTS:
The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.
REGISTRATION NUMBER:
10.17605/OSF.IO/G6N3P.
AuthorsLu Chen, Yanping Chen
JournalMedicine (Medicine (Baltimore)) Vol. 100 Issue 22 Pg. e26155 (Jun 04 2021) ISSN: 1536-5964 [Electronic] United States
PMID34087872 (Publication Type: Journal Article)
CopyrightCopyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Chemical References
  • Anti-Asthmatic Agents
  • Omalizumab
  • Immunoglobulin E
Topics
  • Anti-Asthmatic Agents (administration & dosage, adverse effects, therapeutic use)
  • Asthma (drug therapy)
  • Child
  • Emergency Service, Hospital (statistics & numerical data)
  • Humans
  • Immunoglobulin E (blood)
  • Omalizumab (administration & dosage, adverse effects, therapeutic use)
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Research Design
  • Respiratory Function Tests
  • Meta-Analysis as Topic
  • Systematic Review as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: